EnWave Corporation heads into its May 21 earnings with a picture that looks less like a short story and more like a licensing snowball — shorts have all but exited, and the deal flow is accelerating.
The most striking data point this week is the near-complete collapse in short interest. Estimated shares short dropped roughly 99% over both the past week and the past month, falling from around 17,500–19,700 shares in early April to just 98 shares by April 28. That is not a squeeze — it reads like a near-total exit by a single small short position. The ORTEX short score has edged down to 25.4, broadly consistent with that retreat, and borrow availability is essentially unlimited at effectively zero utilization against a 52-week peak of just 14%. Cost to borrow, at 1.64%, remains unremarkable — it doubled over the past month but that reflects a thin, low-activity lending market rather than any sign of stress.
What the short data cannot fully explain, the news flow does. EnWave inked two new licensing deals in April. On April 7 the company signed an R&D license with Rhizome Food and Farming, the venture linked to Michelin-starred chef Dan Barber. On April 15 it added a commercial license with The Dry Hub to establish REV™ vacuum-microwave drying operations in Egypt — the first African footprint for the technology. The company's CEO also gave a media interview mid-month reinforcing the recurring, asset-light licensing and royalty model. Deal velocity has picked up meaningfully, and each agreement has the potential to become a royalty stream once the licensee reaches commercial scale.
Analyst coverage remains thin and the most recent price target on record — a buy-rated $0.80 CAD — is more than seven months old, making it unreliable as a current reference point. The stock trades at CAD $0.265, roughly a third of that target, but without a fresh estimate it would be misleading to frame that gap as analyst-implied upside. Factor scores carry a more current signal: EnWave ranks in the 96th percentile on short score rank and the 99th on days-to-cover rank — both metrics that describe a stock where short pressure is negligible relative to the broader universe.
The price itself has been soft. EnWave closed the week at CAD $0.265, off 1.9% on the day and down 7% over the past month. That modest decline has come despite back-to-back licensing announcements, suggesting investors are waiting for royalty revenues from these new partners to materialise before re-rating the stock. The six-month chart shows a range between roughly $0.26 and $0.42, with the stock currently pressing the lower end.
The earnings track record adds a note of caution. The two most recent prints both produced day-one declines — down roughly 1.5% and 5.9% respectively — with five-day moves extending those losses. The next scheduled event is May 21. Between now and then, the question is whether the Rhizome and Dry Hub deals can generate enough commercial excitement to shift the price, or whether investors hold off until the company can put actual royalty numbers on the table.
See the live data behind this article on ORTEX.
Open ENW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
